Viking Therapeutics

Phase A — Understand the business

Lens 1 · Company Overview

Viking Therapeutics is a San Diego development-stage biopharma (incorporated Delaware, Sept 2012; IPO Nasdaq:VKTX April 2015) with no marketed products and no revenue — its entire value is a clinical pipeline in metabolic and endocrine disease . The asset that *is* the company is **VK2735**, a dual GLP-1 / GIP receptor agonist (same receptor-pair mechanism class as Lilly's tirzepatide) being developed in **both subcutaneous (weekly injection) and oral (daily tablet) formulations** for obesity .

The company's founding genetics matter: in 2012 CEO Brian Lian, then a sell-side biotech analyst, identified five diabetes/metabolic candidates Ligand Pharmaceuticals wanted to out-license, negotiated the license, and took a $2.5M seed from Ligand to launch Viking ``. So the IP estate originated as in-licensed Ligand chemistry (VK2809, VK0214, VK5211) plus internally developed programs (the DACRA amylin program) layered on top.

• "Customers": none yet — there is no commercial product. The real customer is a future acquirer or, post-approval, payers/PBMs and obesity prescribers. The named near-term counterparty is the manufacturing partner (see Lens 2).
• Suppliers / contract structure: the single most important commercial contract is the March 2025 CordenPharma manufacturing agreement — Viking prepays $150M over three years for API + finished-product supply, securing annual capacity of up to ~200M injectable doses + ~1B oral tablets, expandable at Viking's option . This is a take-or-pay-style prepayment (the 10-Q lists "the ability of CordenPharma to achieve its prepayment milestones" as a capital-requirement driver) .
• Competitors: Eli Lilly (tirzepatide/Zepbound, oral orforglipron) and Novo Nordisk (semaglutide/Wegovy, CagriSema, oral amycretin) are the incumbents; the small-cap peer set is Structure Therapeutics, Altimmune, and the just-acquired Metsera (see Lens 7).

Lens 2 · Supply Chain

For a pre-commercial biotech the "supply chain" is the drug-development value chain, and Viking's is unusually concentrated by design:

Upstream peptide/small-molecule API → CordenPharma (single named CDMO) for both API and fill-finish across SC autoinjectors, vials/syringes, and oral tablets `` → Viking (sponsor, IP owner, clinical operator) → CROs running VANQUISH-1/-2 and VENTURE trials (Viking explicitly does not run its own commercial manufacturing) → eventual specialty/retail pharmacy + payer channel post-approval.

• Chokepoint / single-source dependency: CordenPharma is effectively the sole disclosed manufacturing chokepoint. The 10-Q flags CDMO milestone execution as a named capital-requirement risk ``. For an obesity drug, manufacturing scale is the binding constraint of the entire category (Lilly and Novo spent years supply-constrained) — so locking 200M injectable + 1B oral doses pre-approval is the chain's strongest link, not its weakest.
• Clinical-supply input: "Prepaid clinical trial and preclinical study costs" of $4.0M at 3/31/26 (down from $8.1M) sit on the balance sheet as advance CRO payments ``.

This lens passes the "names or it didn't happen" test: the one name that matters — CordenPharma — is the entire manufacturing chain, and it is contractually nailed down.

Lens 3 · Competitive Advantages (moats)

Viking's moat is not durable in the Buffett sense — it is a pre-approval biotech whose protection is (a) clinical data, (b) IP, and (c) a manufacturing head-start, all of which a $700B Lilly can out-spend. Honest framing:

• Data / efficacy moat (real but contested): VK2735's published numbers are best-in-class on speed — oral up to 12.2% weight loss at 13 weeks, SC up to 14.7% at 13 weeks in Phase 2 ``. The bull's entire thesis is that these short-duration curves had not plateaued, implying a far higher 68–78-week Phase 3 number. That is the moat — if Phase 3 confirms it.
• Dual SC + oral optionality: Viking is one of very few players carrying a credible both-formulations shot on the same molecule. Oral is the larger TAM (no cold chain, no needles); SC is the deeper-efficacy product. Most small-cap peers have one or the other.
• Manufacturing moat: the CordenPharma capacity (Lens 2) is a genuine differentiator vs. Structure/Altimmune — Viking has pre-solved the category's #1 commercial bottleneck ``.
• IP enforcement track record: Viking is winning an offensive trade-secret case protecting the VK2735 estate (ITC ruled in its favor, full ITC affirmed May 2025 with sanctions against Ascletis; now on Federal Circuit appeal) ``. A small biotech that successfully defends its IP at the ITC has a sharper-than-average moat for its size.
• Bargaining power: essentially none today (pre-revenue, dependent on capital markets and a single CDMO). Post-approval, pricing power in obesity is structurally weak — it is a price-war category dominated by two giants who can discount.

Lens 4 · Segments

n/a — single-asset, pre-revenue. There are no reportable revenue segments; segments.csv is empty by design . The only meaningful "segment" breakdown is spend by program, and the company states it **does not track total R&D by program, candidate, or phase** . The one disclosed split is by cost type:

``

The story this tells: clinical-development spend quadrupled YoY as the VANQUISH-1/-2 Phase 3 program (initiated June 2025, ~5,650 combined patients, 78-week dosing) hit full enrollment and full burn. This is the single most important number in the dossier — see Lens 5.

---

Phase B — Measure performance (clinical overlay)

Lens 5 · Pipeline by Phase (swapped from Earnings Result)

The asset table is the company. Every program:

Pleiotropic / formulation profile (the GLP-1 axis that matters): VK2735 is a dual incretin (GLP-1 + GIP) — deeper-efficacy mechanism than pure GLP-1 agonists — and uniquely carries both the high-efficacy SC and the mass-market oral shot. The clinical question is no longer "does it work" (Phase 2 cleared on both) but "does the Phase 3 magnitude justify a $4B+ valuation against incumbents already at Phase 3 / approval."

Latest financial print (Q1 2026, the burn story): Revenue $0. R&D $150.2M (+262.8% YoY), driven by a +$103.2M increase in clinical-study costs — Phase 3 ramp, not a one-time license . G&A $14.0M (flat). Net loss **$158.3M** (vs $45.6M Q1 2025); EPS **$(1.37)** vs $(0.41). Operating cash burn **$113.9M** for the quarter (vs $52.3M) . The quarterly burn rate more than doubled as Phase 3 went to full cost.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts/ empty). From web: the Q1 2026 call framed the quarter around VANQUISH-2 enrollment completion and the Q3 2026 SC maintenance-dosing readout as the next catalyst . Management's recurring posture across 2025–26 has shifted from *"can the molecule deliver"* (Phase 2 era) to *"executing late-stage at scale + securing supply"* — the CordenPharma deal and the move to a larger San Diego HQ (25,062 sq ft from April 2026, lease to 2031) signal a company building for commercialization, not optionality . Tone is confident; the market's tone is the opposite (Lens 8). That gap is the trade.

Lens 7 · Catalyst Calendar + Mechanism Comps (swapped from P/E comps)

Pre-revenue obesity names cannot be compared on EV/Sales or P/E — n/a, not sourced for all earnings multiples (no revenue, no earnings). The honest comp is by mechanism, stage, market cap, and cash:

Catalyst calendar (what de-risks or kills each program, and when):

• Q1 2026 — DACRA IND filing ``.
• Q3 2026 — VK2735 SC maintenance-dosing data — the next real binary; speaks to durability + the q2w/monthly dosing story that would differentiate vs. weekly incumbents ``.
• H1 2027 — oral maintenance data.
• 2027 — VANQUISH-1 + VANQUISH-2 topline — the company-defining event; full Phase 3 obesity magnitude ``.
• Ongoing — oral VK2735 Phase 3 initiation; any VK2809 NASH partnering.

The Metsera/Pfizer $10B takeout reset the M&A comp for the whole group — proof of big-pharma appetite, but it also removed Pfizer as a Viking acquirer (see Lens 13).

Lens 8 · Stock-Price Catalysts (what moves VKTX >5%)

VKTX trades almost entirely on binary clinical headlines and competitor read-through, not fundamentals (there are none). Pattern from the last ~18 months ``:

• Phase 2 oral data reaction (early 2026): shares sold off hard enough that short sellers booked a $521M one-day paper gain — the market judged the oral data against Lilly's orforglipron and found it wanting on a (flawed) cross-trial basis ``.
• Competitor prints move the stock: Lilly orforglipron ATTAIN data, Novo CagriSema, and Pfizer's obesity entry all moved VKTX ``.
• 52-week range $22.96–$43.15, last ~$30 (Jun 17 2026) — i.e. trading in the lower third of its range ``.
• Short interest ~22–28% of float (~25–26M shares) — extraordinarily high; this is a battleground where any clean Phase 3 win is a violent squeeze and any stumble is a trap-door ``.
• Ownership: ~50% retail, ~32% institutions, Ligand 8.8%, CEO 2.4% — a retail-driven, sentiment-amplified tape ``.

The lesson: the market reacts to (a) Viking's own readouts and (b) every competitor data drop — VKTX is a high-beta proxy on "is there room for a third obesity franchise."

---

Phase C — Judge people & books (+ science & exclusivity)

Lens 9 · Management

• Track record: CEO Brian Lian, Ph.D. (organic chemistry, Michigan; MBA Indiana) — founder since 2012. His signature act of value creation is Viking: as a sell-side analyst he spotted the under-valued Ligand metabolic portfolio, licensed it, seeded the company, and IPO'd it in 2015 ``. Prior: drug-discovery scientist at Amgen + Microcide, then senior biotech equity analyst (CIBC, SunTrust Robinson Humphrey, Global Hunter). A rare scientist-financier hybrid — he can read the data and the capital markets.
• Tenure & skin in the game: 14 years, founder-CEO. Directly owns ~2.4% of shares; original sponsor Ligand still holds 8.8% ``. Meaningful insider alignment for a company this size.
• Capital allocation: disciplined for a biotech — raised opportunistically at strong prices (March 2024 follow-on: 7.44M shares at $85.00 for $597.1M net — i.e. issued near the highs) . Pre-funded manufacturing via CordenPharma. **Oddity worth flagging:** a Feb 2025 board authorization for a **$250M buyback** (none executed) — a buyback at a cash-burning, pre-revenue biotech is unusual signaling; reads as a "we think the stock is cheap / management confidence" gesture more than a real capital-return plan .
• Red flags: none material. No related-party self-dealing surfaced; comp is not flagged as egregious in filings. The Ligand relationship is an arm's-length royalty/license, disclosed.
• Archetype: founder-operator (not a parachuted professional manager) — the right archetype for a high-conviction, single-asset, swing-for-the-fences late-stage biotech.

Lens 10 · Forensic Red Flags

For a pre-revenue, single-asset biotech the accounting surface is small and clean — the risk is dilution + going-concern, not revenue games:

• Revenue recognition: n/a — $0 revenue ``.
• Cash vs. earnings divergence: net loss $158.3M vs. operating cash burn $113.9M — the gap is mostly non-cash SBC ($10.3M) + working-capital timing (accruals/payables rose). Nothing anomalous ``.
• Balance sheet: clean and liquid — $603.0M cash + ST investments, zero debt, $501.9M equity, accumulated deficit $1,005.9M (crossed $1B in deficit this quarter — the cost of the bet to date) ``. Investments are US-govt + investment-grade corporates, conservatively managed.
• SBC / non-GAAP flattering: SBC $10.3M/quarter is modest relative to burn — it is not being used to dress up a non-GAAP narrative (there is no non-GAAP EPS to flatter). Honest.
• Dilution risk (the real flag): share count rose from 111.6M (12/31/24) → 115.9M (3/31/26); active ATM with $63.7M remaining, a shelf (expires July 2026), and an explicit "we will need to raise additional capital" statement ``. At a >$110M/quarter burn, another raise is a when-not-if before VANQUISH topline — the dilution overhang is structural.
• Internal controls: management concluded disclosure controls effective; a new accounting system was implemented in Q1 2026 (controls modified, under evaluation) — worth watching but routine ``.

Regulatory findings (required):

• SEC Litigation Releases / AAERs: None. Zero LR and zero AAER naming Viking in 2021–2026, verified via SEC EDGAR EFTS ``.
• 10-K Item 3 (Legal Proceedings): Viking is not a defendant in any material litigation. Notably, Viking is the plaintiff/winner in an offensive trade-secret action — Viking v. Ascletis et al. (filed Dec 2022): the ITC's Chief ALJ ruled in Viking's favor (Oct 3 2024), the full ITC affirmed (May 29 2025) finding Ascletis misappropriated Viking's trade secrets under an NDA + engaged in discovery misconduct, with monetary + non-monetary sanctions; now on cross-appeal at the Federal Circuit ``. This is an IP-strength signal, not a liability.
• Non-SEC enforcement (FDA/FTC/DOJ): no material enforcement hits surfaced in web search; as a pre-commercial company it has no marketed-product regulatory exposure yet.
• Conclusion: No material regulatory or legal findings against the company — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-18.

Science & exclusivity (clinical overlay sub-section):

• Mechanism validation: dual GLP-1/GIP agonism is the most clinically validated obesity mechanism on the market — tirzepatide (same pair) is a multi-tens-of-billions franchise. Viking is not taking mechanism risk; it is taking execution + magnitude + competitive-timing risk.
• IP estate: rooted in the Ligand license + internal DACRA chemistry; actively defended (ITC win above). Patent-cliff/LOE is not the near-term issue — approval and competitive share are.
• Reimbursement path: obesity coverage is improving but remains a payer battleground; a third entrant will face price pressure from Lilly/Novo. The oral formulation's lower cost-of-goods is the reimbursement edge.

---

Phase D — Project & stress-test

Lens 11 · rNPV + Runway-to-Catalyst (swapped from EPS projection)

Pre-revenue → no EPS to forecast (losses widen for years). The two questions that matter:

(1) Does cash runway reach the next value-inflection catalyst?

• Cash + ST investments at 3/31/26: $603.0M ``.
• Company guidance: sufficient "through at least June 30, 2027" ``.
• Q1 2026 operating burn: $113.9M → annualized ~$456M ``. On cash alone that is ~5.3 quarters → ~mid-2027, consistent with the company's June-2027 statement but tight against VANQUISH topline (2027).
• Verdict: runway reaches the Q3 2026 SC maintenance readout and the oral Phase 3 start comfortably, and probably reaches VANQUISH topline — but with thin margin if Phase 3 costs keep climbing. Expect at least one capital raise (equity, ATM, or a partnership) before the defining 2027 readout. The $63.7M ATM + shelf are the pre-loaded tools ``.

(2) Risk-adjusted NPV of the lead asset (illustrative, every input labeled):

• Obesity TAM is enormous (consensus tens of billions; Lilly+Novo franchises already prove it) ``.
• Illustrative rNPV frame for VK2735 (SC + oral combined), **— not a sourced model:** peak unadjusted sales of, say, $3–5B for a successful #3 dual-incretin franchise × a Phase-3-stage probability-of-success (industry base rate for obesity Phase 3 ≈ 55–70% given Phase 2 already cleared) × a high biotech discount rate (~12–15%), net of remaining development cost and dilution. Against a **$3.97B market cap**, the market is pricing **meaningful-but-not-certain** Phase 3 success and a partial takeout premium — i.e. *not* a lottery ticket, but *not* free optionality either. The analyst mean target ~$92 (≈ +196% vs. ~$30) implies the Street models a far higher rNPV than the tape. The gap between $30 tape and $92 consensus is the entire debate.

Brier forecast to log (per overlay — log the next binary, not an EPS line): "VK2735 Phase 1 SC maintenance-dosing study (Q3 2026) reports clinically supportive durability data, p≈0.70." (Not logged via forecast.ts — breadth/watchlist loop skips the create step per SKILL.)

Lens 12 · Bull vs Bear

Bull case. Viking owns the single best obesity asset not yet inside Big Pharma — a dual GLP-1/GIP with both a best-in-class-speed SC and a viable oral, Phase 2 cleared on both, Phase 3 fully enrolled, and — critically — manufacturing already locked via CordenPharma (200M injectable + 1B oral doses), which pre-solves the category's binding constraint ``. The Phase 2 curves hadn't plateaued at 13 weeks, so a clean VANQUISH topline in 2027 could print a magnitude that forces a re-rate and makes Viking the obvious takeout for any of the ~6 large pharmas without a credible second-gen obesity asset. With ~22–28% short interest, that print is a squeeze. Management is a founder-scientist-financier who issues stock at the highs and owns 2.4%.

Bear case. Three ways this permanently impairs:

1. The oral is late and Lilly is lapping it. Lilly's oral orforglipron already has Phase 3 ATTAIN-1 data (12.4% at 72 weeks) and global regulatory submissions in flight ``. Viking's oral is only entering Phase 3. By the time VK2735 oral could launch, Lilly (and possibly Novo's amycretin) own the oral shelf with infinite supply and pricing power. A third oral entrant into a Lilly/Novo price war is a commodity, not a franchise.
2. Cross-trial efficacy mirage. The bull's "12.2% at 13 weeks beats 12.4% at 72 weeks" is a category error — different phase, different duration, different population. Phase 3 obesity magnitudes routinely come in below buzzy Phase 2 reads; a VANQUISH topline that merely matches incumbents (rather than beats) de-rates the stock even on a "successful" trial.
3. Dilution + the takeout that may not come. Burn >$110M/quarter guarantees more dilution before 2027; and the Metsera/Pfizer $10B deal removed one of the most logical acquirers while giving Novo/Pfizer their own assets — the takeout bid the price partly relies on may have just walked.

Pre-mortem (18 months out, thesis broke): VANQUISH-1 topline (2027) prints solid-but-unremarkable ~15–18% weight loss — efficacious, FDA-able, but not differentiated vs. Zepbound; meanwhile Lilly's oral is approved and discounting. No takeout materializes (acquirers covered). Viking raises dilutive equity into a falling stock to fund commercialization it can't out-market. Shorts win.

Multiples too high? There are no earnings multiples; the question is whether a $3.97B cap on a single Phase-3 asset facing two giants is too rich. It is fully-valued, not cheap — it embeds a high P(success) and a takeout option.

Contrarian view (what the market refuses to see): the market is anchored on efficacy vs. Lilly and missing that manufacturing + the oral/SC dual-shot is the actual differentiator, and that the most likely path to value isn't a standalone launch at all — it's a take-out by a pharma (AstraZeneca, Roche, Amgen, Merck) that has no credible obesity asset and for whom $10–15B for the best independent dual-incretin is rounding error. The Metsera deal proved the price; it didn't exhaust the buyers.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull:

• Revenue concentration = 100% on one molecule's Phase 3. There is no diversification, no revenue, no floor. A single VANQUISH miss is a >50% drawdown. VK2809 (NASH) and VK0214 (X-ALD) are partner-it-or-shelve afterthoughts, not a backstop.
• The moat is a mirage against scale. "Best efficacy" evaporates if Phase 3 only matches incumbents — and Lilly/Novo can match Viking's price to zero margin while Viking needs margin to fund itself. Switching costs in obesity favor the incumbent with supply and a CV-outcomes label.
• Most dangerous competitor bulls underestimate: Lilly's oral. orforglipron is a small molecule (cheaper to make than Viking's peptide oral), already Phase 3, already filing ``. If the future of obesity is the pill, Lilly is years and billions ahead.
• Capital-allocation tell: the $250M buyback authorization at a pre-revenue burner is promotional — it signals management is managing the stock (and the ~25% short base) as much as the science.
• Assumptions that must hold for $30, let alone $92: (a) VANQUISH magnitude ≥ incumbents, (b) a takeout premium, (c) manageable dilution, (d) the oral isn't commoditized by Lilly first. Break any one and the rNPV halves.
• If growth/efficacy disappoints 20–30%: a Phase 3 weight-loss number ~20–30% below the Phase 2 buzz (i.e. low-teens %) is still "positive" but strips the differentiation thesis → re-rate toward cash-plus-modest-option value, well below current cap.
• Single scenario that permanently impairs: VANQUISH topline shows a tolerability/SAE signal (GI-driven discontinuations, or a safety flag) at Phase 3 scale that Phase 2 (small N) missed — for a third-entrant in a category with two clean incumbents, a safety asterisk is fatal to both the launch and the takeout. Plausibility: low-to-moderate, but it is the tail that ends the story.

Lens 14 · Management Questions (ordered by information value)

1. VANQUISH-1 topline: what placebo-adjusted weight-loss magnitude at 78 weeks would you consider a competitive win vs. tirzepatide, and what would you consider a disappointment?
2. Given Lilly's oral orforglipron is already filing, what is VK2735 oral's differentiated path — efficacy, tolerability, cost-of-goods, or dosing — and is a standalone oral launch even the plan?
3. Is the base case a standalone commercial launch, or is this company being built to be acquired? How do those two paths change your capital and hiring decisions today?
4. Walk through the runway: at the current >$110M/quarter burn, when do you expect to raise, how much, and via what instrument (ATM, follow-on, or a development/commercial partnership)?
5. What did the Q3 2026 SC maintenance-dosing study need to show for you to feel good about durability and a differentiated dosing schedule (q2w/monthly)?
6. CordenPharma: what are the prepayment-milestone triggers, what happens to the $150M and to supply if a milestone slips, and is the capacity truly expandable on the timeline a launch would need?
7. On tolerability at Phase 3 scale — what GI-discontinuation and SAE rates are you seeing blind, and how do they track vs. the Phase 2 profile?
8. Why authorize a $250M buyback at a pre-revenue, cash-burning company — and under what conditions would you actually execute it?
9. For VK2809 (NASH) and VK0214 (X-ALD): partner, advance, or shelve — and on what timeline, so they aren't a distraction from VK2735?
10. What is your contingency if a Big Pharma launches a price war the moment VK2735 approaches market — can a single-product company fund a commercial fight against Lilly/Novo?
11. The DACRA amylin program: post-IND (Q1 2026), how does it fit — combination with VK2735, a follow-on, or optional?
12. How do you think about the obesity TAM splitting between SC and oral, and where does VK2735's value concentrate in five years?
13. What is the status and financial exposure of the Ascletis trade-secret appeal at the Federal Circuit, and what does winning vs. losing change?
14. Insider ownership and alignment: any plans to add to your stake, and how is the team incentivized on a takeout vs. a standalone outcome?
15. What is the single risk that keeps you up at night that the Street is not asking about?

---